Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Celgene's Terrie Curran On Building, Broadening The I&I Franchise

Executive Summary

Celgene has hit multiple roadblocks in building its inflammation and immunology (I&I) portfolio, but it has a lot of potential shots on goal to eventually help the company diversify its revenue beyond the cancer blockbuster Revlimid, starting with flagship product Otezla.


Related Content

Ilumya Becomes Sun's New Branded Specialty Drug Pillar
More Bad News: Celgene Reveals Refuse-To-File Letter For Ozanimod In MS
AAD Roundup: Sun Sets Sights On Psoriasis As Competitive Pressures Mount
Celgene's IBD Franchise Boosted by Otezla Ulcerative Colitis Success
Celgene Focuses On Deals, Pipeline As Post-Revlimid Future Draws Closer
Celgene's Partnered Pipeline Delivers Successes And Setbacks
Celgene Admits It Screwed Up Otezla Estimates; Investors Lose Confidence
Celgene IBD Pipeline In Question As Mongersen Crohn’s Disease Trial Ends
4-in-1 deal: Forma grabs $225m from Celgene
BioNotebook: Medivation, Clovis, Arena 4Q updates; Abide/Celgene discovery deal; 3 new IPO filers, 2 other set terms


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts